Sort
10,766 grants matching “checkpoint inhibitor”
Regulation of Chromosome Segregation in Human Cells
$468,210Prasad V Jallepalli · Sloan-Kettering Inst Can Research · R01 · FY2018 · GM
An innate immune checkpoint in cancer immunotherapy
$468,186Carla Rothlin · Yale University · R01 · FY2018 · CA
Targeting UHRF1 in combinational immunotherapy
$468,148Xiao-Fan Wang · Duke University · R01 · FY2020 · CA
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
$468,091Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
$468,091Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2023 · CA
Targeting the innate immune response in HNSCC
$468,023Judith A. Varner · University Of California, San Diego · R01 · FY2017 · DE
Multiscale Computational Models Guided By Emerging Cellular Dynamics Quantification For Predicting Optimum Immune Checkpoint And Targeted Therapy Schedules
$467,951Trachette Jackson · University Of Michigan At Ann Arbor · U01 · FY2024 · CA
Targeting apoptotic caspases to enhance cancer radiotherapy
$467,757Chuan-Yuan Li · Duke University · R01 · FY2021 · CA
Targeting apoptotic caspases to enhance cancer radiotherapy
$467,757Chuan-Yuan Li · Duke University · R01 · FY2020 · CA
PI3K/PTEN/Akt signaling and the genesis of cancer
$467,725Nissim Hay · University Of Illinois At Chicago · R01 · FY2025 · CA
PI3K/PTEN/Akt signaling and the genesis of cancer
$467,549Nissim Hay · University Of Illinois At Chicago · R01 · FY2023 · CA
Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patients
$467,492Scott H Kaufmann · Mayo Clinic Rochester · R01 · FY2024 · CA
Head & Neck Cancer Neoantigen Characterization & Therapeutic Targeting
$467,480Young J. Kim · Vanderbilt University Medical Center · R01 · FY2019 · DE
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer
$467,377Alice Berger · Fred Hutchinson Cancer Research Center · R37 · FY2021 · CA
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer
$467,377Alice Berger · Fred Hutchinson Cancer Center · R37 · FY2022 · CA
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer
$467,377Alice Berger · Fred Hutchinson Cancer Center · R37 · FY2025 · CA
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy
$467,098J. Silvio Gutkind · University Of California, San Diego · R01 · FY2021 · DE
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
$466,898Xinna Zhang · Indiana University Indianapolis · R01 · FY2023 · CA
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
$466,898Xinna Zhang · Indiana University Indianapolis · R01 · FY2025 · CA
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors
$466,837Seth M Pollack · Northwestern University At Chicago · R01 · FY2024 · CA
Project 3: The AMPK Autophagy Pathway as a Metabolic Liability in Pancratic Ductal Adenocarcinoma
$466,752Reuben J Shaw · Salk Institute For Biological Studies · P01 · FY2023 · CA
Project 3: The AMPK Autophagy Pathway as a Metabolic Liability in Pancratic Ductal Adenocarcinoma
$466,751Reuben J Shaw · Salk Institute For Biological Studies · P01 · FY2025 · CA
Novel DNA damage response therapeutics targeting replication protein A
$466,687John J Turchi · Indiana University Indianapolis · R01 · FY2024 · CA
Regulation of DNA double-strand break repair pathway choice
$466,640Wolf-Dietrich Heyer · University Of California At Davis · R01 · FY2023 · CA
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
$466,587Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2024 · CA